Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 11/20 | 0.56 |
| ▸ | PARP1 | P09874 | 6/20 | 0.56 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.56 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PARP11 | Q9NR21 | 7/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25797924 | 0.86 | PARP10 (0.51) | PARP10PARP1F7F3MAPKAPK2 | |
| Hydrochloric Acid SCHEMBL12077362 | 0.85 | PARP10 (0.50) | PARP10PARP1F7F3MAPKAPK2 | |
| SCHEMBL29920598 | 0.82 | NTRK2 (0.47) | PARP10PARP1F7F3MAPKAPK2 | |
| SCHEMBL19152767 | 0.79 | PARP10 (0.56) | PARP10PARP1F7F3KDM4E | |
| SCHEMBL14107468 | 0.76 | PARP10 (0.55) | PARP10PARP1F7F3MAPKAPK2 | |
| SCHEMBL21326161 | 0.76 | PARP10 (0.51) | PARP10PARP1F7F3MAPKAPK2 | |
| SCHEMBL22607406 | 0.76 | PARP10 (0.51) | PARP10PARP1F7F3KDM4E | |
| SCHEMBL18238060 | 0.76 | PARP10 (0.47) | PARP10PARP1F7F3CDC7 | |
| SCHEMBL3579503 | 0.75 | MAPKAPK2 (0.66) | MAPKAPK2CDC7ROCK2MAP4K4CDK2 | |
| SCHEMBL31696655 | 0.74 | PBRM1 (0.46) | GRM5MAPK1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| EP-3706742-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| US-10947234-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200361931-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-19 | — | — | US | disclosed |
| EP-3706742-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361931-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | PARP10 142/4885PARP1 319/4885F7 4512/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | PARP10 2366/4885PARP1 3496/4885F7 4649/4885 |
| US-10947234-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | PARP10 142/4885PARP1 319/4885F7 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.